An Official Methadone Anonymous SUPPORT Website!


Buprenorphine (Suboxone/Subutex)

Be notified of
page updates
it's private
powered by
ChangeDetection






PRESS RELEASE

FOR IMMEDIATE RELEASE:
February 23, 2008
Contact: Chuck Hilger, CMG
chilger2@earthlink.net

CMG Now Offering Suboxone


Colonial Management Group (CMG), with 54 opiate addiction treatment centers located throughout the United States, announced that as of January 1, 2008 all of their facilities are now offering Buprenorphine (Brand name Suboxone) in addition to their Methadone Maintenance Program.

Suboxone (Buprenorphine/Naloxone) received approval by the FDA on October 8, 2002. It is state of the art medication to treat the medical condition of Opioid addiction. It is improving the quality of life for patients in recovery and giving them hope, dignity, and the ability to have a normal life again.


Cash only, please!

Addicts' Cure has Fatal Flaw (doc)




Buprenorphine Maintenance Versus Placebo or Methadone

The Cochrane Review (pdf)




Interesting Description of how Buprenorphine Works

How Buprenorphine Works (pdf)

Gracer Medical Group
Richard I. Gracer, M.D.



Here is some GREAT information from the SAMHSA Website on Buprenorphine....


About Buprenorphine Therapy

In October 2002, the FDA approved buprenorphine monotherapy product, Subutex®, and a buprenorphine/naloxone combination product, Suboxone®, for use in opioid addiction treatment. The combination product is designed to decrease the potential for abuse by injection. Subutex® and Suboxone® are currently the only Schedule III, IV, or V medications to have received FDA approval for this indication.

Note that aside from Subutex® and Suboxone®, other forms of buprenorphine, e.g., Buprenex®, are not approved for treatment of opioid addiction.

The FDA approval of these buprenorphine formulations does not affect the status of other medication-assisted opioid addiction treatments, such as methadone and LAAM (levo-alpha-acetyl-methadol). As indicated in Title 42 Code of Federal Regulations Part 8 (42 CFR Part 8), these treatments can only be dispensed, and only in the context of an Opioid Treatment Program. Also, neither the approval of Subutex® and Suboxone®, nor the provisions of DATA 2000, affect the use of other Schedule III, IV, or V medications, such as codeine, that are not approved for the treatment of addiction.

Lastly, note that aside from Subutex® and Suboxone®, other forms of buprenorphine, e.g., Buprenex®, are not approved for treatment of opioid addiction.


[READ MORE]



BUPRENORPHINE PHYSICIAN LOCATOR

http://buprenorphine.samhsa.gov/bwns_locator/index.html

**Naabt.org now has an improved search feature of the SAMHSA list of certified prescribers. It now includes proximity searching that automatically displays certified prescribers sorted from the closest to the zip code a patient entered. This helps people near geographical borders, and approximates how far one would need to travel for treatment.

Click the “Patient / Doctor Connection” button on any page at naabt.org or click the link below to try it:

New Physician locator (SAMHSA data):

http://naabt.org/patient_dr_connection.cfm

FREQUENTLY ASKED QUESTIONS

http://buprenorphine.samhsa.gov/faq.html

PUBLICATIONS

http://buprenorphine.samhsa.gov/publications.html

ADDITIONAL RESOURCES

http://buprenorphine.samhsa.gov/otherlinks.html

* 2013 *
FDA Approves Two Generic Versions of Suboxone
FINALLY!!
Read more!









Check out this great organization!!

naabt.org - National Alliance of Advocates for Buprenorphine treatment


http://www.naabt.org/buprenorphine_overview.cfm


If you are just beginning to learn about Buprenorphine or want to explain it to someone,
following are the most important points to know...

TOP 15 MOST IMPORTANT THINGS TO KNOW ABOUT BUPRENORPHINE/SUBOXONE®

  1. Eliminates cravings - and withdrawal symptoms in opioid dependent people.


  2. Less abusable – does not produce strong euphoria like other opioids, likely to cause withdrawal if abused.


  3. Ceiling effect – cannot achieve a “high” from taking more than prescribed. This means that someone cannot overdose on Buprenorphine alone, when taken sublingually.


  4. Blocking effect – cannot get high from using other opiates (heroin, OxyContin, Vicodin, etc.) while taking Buprenorphine.


  5. Safe – side effects are similar to, but milder than, the opioid someone is trying to get off of. Does not impair or intoxicate the patient.


  6. Long lasting – up to 72 hours.

  7. Fast-acting results – many people feel the effects within minutes of their first dose.


  8. Prescribed in the privacy of a doctor’s office – no one needs to know except the doctor and the patient. Pick up medication weekly or monthly in a pharmacy not daily in a clinic.


  9. Immediate return to work – no time lost to “adjusting” to the medication or stays in a rehabilitation facility.


  10. When diverted to the streets, it is still used for its indication, not abused. Not a desirable choice for the abuser.


  11. Required dosage does not increase with time (unlike with methadone or any other opioid).


  12. Has shown effectiveness in treating refractory depression and pain.


  13. Because cravings are gone, it allows the individual to focus on the underlying reasons for the addiction.


  14. Dependency is less likely than with other opioids and Buprenorphine is easier to discontinue.


  15. Doctors must take an 8-hour class to prescribe and are limited by law, to only treating 30 patients at any one time.


*NAABT.org has an interactive Buprenorphine newsletter*

February '07 Newsletter:

http://www.MethadoneSupport.org/naabt_Feb07.pdf

(it can also be found on the home page of www.naabt.org)




http://www.usdoj.gov/ndic/pubs10/10123/


A New Form of Buprenorphine Administration

A new, extended-release formulation of buprenorphine, called a depot formulation, currently is being developed. This depot formulation is an injectable solution that contains tiny biodegradable capsules of buprenorphine. As the capsules disintegrate, they slowly release the drug over several weeks. This new formulation of buprenorphine is designed for administration in a physician's office once every 4 to 6 weeks and could further safeguard against diversion by eliminating the need for patients to possess buprenorphine in tablet form.








More Reading....


"The Bitter Pill"...from Wired Magazine










[ Home ] [ What is Methadone? ] [ URGENT ISSUES!! ] [ Methadone Anonymous ] [ Meetings by State ] [ Online Meetings ] [ Buprenorphine ] [ Forums ] [ HCV/HIV News ] [ Methadone News ] [ Resources/Links ] [Creative Recovery ] [Around the World ] [Events ] [Recovery Stories ] [Advisory Board ] [ Methadone Pregnancy Info. ] [ ADVOCACY ]



Copyright © 2005 BARBSHOL